Abstract：
Non muscle invasive bladder cancer (NMIBC) has unpredictable outcomes with a variable risk of recurrence and progression. Many clinic-pathological prognostic factors have been identified but remain insufficient, raising the need to investigate new biomarkers. The aim of our study was to assess the prognostic value of the immunohistochemical (IHC) markers E-Cadherin and B-Catenin in NMIBC. All cases of NMIBC were collected between 2008 and 2013. IHC analysis was performed using E-Cadherin and B-Catenin. Reduced or loss of E-Cadherin expression was assessed as abnormal. Only cases with B-Catenin intense membranous staining were considered normal. A correlation was found between abnormal E-Cadherin expression and stage (p = 0.001), grade (p = 0.0000000), recurrence (p = 0.0000000), progression (p = 0.01), recurrence-free survival (p = 0.00000001), and progression-free survival (p = 0.01). A statistically significant association was found between B-Catenin and stage (p = 0. 05), grade (p = 0.02), and recurrence (p = 0.02). The abnormal expression of these markers could help to identify a high-risk subgroup of NMIBC that might benefit from either more accurate follow-up or more aggressive treatment.
摘要：
非肌层浸润性膀胱癌(NMIBC)具有不可预测的结果,具有可变的复发和进展风险。已经确定了许多临床病理预后因素，但仍然不足。提高了研究新生物标志物的必要性。我们研究的目的是评估NMIBC中免疫组织化学（IHC）标记E-Cadherin和B-Catenin的预后价值。所有NMIBC病例均在2008年至2013年之间收集。使用E-Cadherin和B-Catenin进行IHC分析。E-Cadherin表达的降低或丧失被评估为异常。只有具有B-Catenin强烈膜染色的病例被认为是正常的。发现E-Cadherin异常表达与分期之间存在相关性（p=0.001），等级（p=0.0000000），复发（p=0.0000000），进展（p=0.01），无复发生存率（p=0.00000001），和无进展生存期（p=0.01）。在B-Catenin和分期之间发现了统计学上的显着关联（p=0。05),等级（p=0.02），和复发（p=0.02）。这些标志物的异常表达可能有助于鉴定NMIBC的高风险亚组，该亚组可能受益于更准确的随访或更积极的治疗。
